{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+immunoglobulins", "query": { "intervention": "Subcutaneous immunoglobulins" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 907, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+immunoglobulins&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T23:42:30.036Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06559163", "title": "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Obexelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zenas BioPharma (USA), LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 190, "start_date": "2024-09-17", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 32, "location_summary": "Peoria, Arizona • Fresno, California • Huntington Park, California + 28 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06559163" }, { "nct_id": "NCT01239043", "title": "Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Meningitis", "Meningococcal Meningitis", "Meningococcal Infections" ], "interventions": [ { "name": "Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide", "type": "BIOLOGICAL" }, { "name": "Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "56 Years", "maximum_age": null, "sex": "ALL", "summary": "56 Years and older" }, "enrollment_count": 139, "start_date": "2010-11", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bardstown", "state": "Kentucky" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "West Jordan", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239043" }, { "nct_id": "NCT03555149", "title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Imprime PGG", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Idasanutlin", "type": "DRUG" }, { "name": "AB928", "type": "DRUG" }, { "name": "LOAd703", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "GENETIC" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2018-09-27", "completion_date": "2022-09-26", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 6, "location_summary": "Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03555149" }, { "nct_id": "NCT02908906", "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "JNJ-63723283", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2016-11-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 2, "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908906" }, { "nct_id": "NCT06593600", "title": "Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postural Orthostatic Tachycardia Syndrome (POTS)" ], "interventions": [ { "name": "REGN7544", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 82, "start_date": "2024-11-13", "completion_date": "2026-07-08", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Carlsbad, California • Palo Alto, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06593600" }, { "nct_id": "NCT02207634", "title": "Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Background Statin Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 1974, "start_date": "2014-09-10", "completion_date": "2016-11-11", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 134, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 123 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02207634" }, { "nct_id": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone/Prenisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2023-11-14", "completion_date": "2029-07-29", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 9, "location_summary": "Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097364" }, { "nct_id": "NCT04118153", "title": "Early Markers of Disease and Response to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandra Lord, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "6 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2021-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 2, "location_summary": "Seattle, Washington • Milwaukee, Wisconsin", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04118153" }, { "nct_id": "NCT04761627", "title": "A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" }, { "name": "ABP 654", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 494, "start_date": "2021-03-24", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 31, "location_summary": "Hot Springs, Arkansas • Beverly Hills, California • Fremont, California + 28 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761627" }, { "nct_id": "NCT00822770", "title": "Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stem Cell Transplantation", "Leukemia" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Allogeneic blood stem cell transplant", "type": "PROCEDURE" }, { "name": "ATG (Thymoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 47, "start_date": "2009-01", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-16T23:42:30.036Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00822770" } ] }